Form 4: Prime Medicine Executive Acquires 275,000 Stock Options
SEC Form 4 Filing
Jeremy Duffield, Chief Scientific Officer of Prime Medicine, Inc., acquired 275,000 stock options on February 27, 2025, at an exercise price of $2.42.
Summary
- Jeremy Duffield, the Chief Scientific Officer of Prime Medicine, Inc., filed a Form 4 on March 3, 2025, reporting a transaction.
- On February 27, 2025, Duffield acquired 275,000 stock options with an exercise price of $2.42.
- The options vest in monthly installments over four years, starting from February 27, 2025, contingent upon continued service.
- The options expire on February 27, 2035.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects a standard executive compensation practice. It doesn't inherently indicate positive or negative performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of the shareholders, incentivizing them to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of the stock option grant and start of vesting period. |
| 02/27/2035 | Expiration date of the stock options. |
| 03/03/2025 | Date the Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.